Skip to main content

Metabolismus und gynäkologische Krebserkrankungen

Metabolism and gynecological cancers


Übergewicht und Adipositas steigern signifikant das Risiko für postmenopausale Mammakarzinome und für Endometriumkarzinome. Auch das Ovarialkarzinom ist mit Übergewicht oder Adipositas assoziiert. Diese erhöhte Inzidenz von gynäkologischen Karzinomen wird auf die typischen Stoffwechselveränderungen bei übergewichtigen/adipösen Frauen (u. a. vermehrte adrenale Androgensynthese, vermehrte periphere Aromatisierung zu Östrogenen, erhöhtes Leptin, Interleukin 6, Tumornekrosefaktor α, Insulin, IGF („insulin-like growth factor“), Hyperglykämie) zurückgeführt, welche die Entstehung und Weiterentwicklung gynäkologischer und anderer Karzinome fördern. Medikamentöse Behandlungsversuche des metabolischen Syndroms mit oralen Antidiabetika (Metformin) und Statinen haben in der Prävention und Therapie gynäkologischer Karzinome nicht überzeugt. Wahrscheinlich wirksam sind dagegen Gewichtsabnahme, Nahrungsumstellung (mediterrane Ernährung) und überwachtes körperliches Training. Bei prämenopausalen Frauen reduzieren Übergewicht oder Adipositas das Brustkrebsrisiko. Es wird vermutet, dass hierfür eine verminderte ovarielle Progesteronproduktion verantwortlich ist. Bei prämenopausalen Frauen erhöhen Übergewicht und Adipositas das Endometriumkarzinomrisiko sowie das von Herz-Kreislauf-Erkrankungen, sodass auch hier eine Gewichtsreduktion und mehr Bewegung sinnvoll sind.


Overweight and obesity are associated with a significant increase in the risk for postmenopausal breast cancer and endometrial carcinoma. Ovarian cancer is also associated with overweight and obesity. This higher incidence of gynecological cancers is explained by the typical metabolic alterations in overweight or obese women, including increased adrenal androgen production, increased peripheral aromatization to estrogens, elevated levels of leptin, interleukin 6, tumor necrosis factor alpha, insulin, insulin-like growth factor (IGF) and hyperglycemia, which promote the formation and development of gynecological and other cancers. Attempts to treat this metabolic syndrome with drugs, such as oral antidiabetics (metformin) and statins were not convincing regarding prevention and treatment of gynecological cancers. In contrast, probably effective are weight loss, change of diet (Mediterranean diet) and supervised physical activity. Overweight or obese premenopausal women have a significantly lower risk for breast cancer, which is assumed to be due to reduced ovarian progesterone production. Overweight or obese premenopausal women have a markedly increased risk for endometrial cancer and cardiovascular diseases. For them weight reduction and increased physical activity are also beneficial.

This is a preview of subscription content, access via your institution.

Abb. 1


  1. 1.

    Argyrakopoulou G, Dalamaga M, Spyrou N et al (2021) Gender differences in obesity-related cancers. Curr Obes Rep 10:100–115.

    Article  PubMed  Google Scholar 

  2. 2.

    Borella F, Carosso AR, Cosma S et al (2021) Gut microbiota and gynecological cancers: a summary of pathogenetic mechanisms and future directions. ACS Infect Dis 7:987–1009.

    Article  PubMed  CAS  Google Scholar 

  3. 3.

    Bruno E, Oliverio A, Paradiso AV et al (2020) A Mediterranean dietary intervention in female carriers of BRCA mutations: results from an Italian prospective randomized controlled trial. Cancers (Basel).

    Article  Google Scholar 

  4. 4.

    Buono G, Crispo A, Giuliano M et al (2020) Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. Breast Cancer Res Treat 182:401–409.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. 5.

    Bustamante-Marin XM, Merlino JL, Devericks E et al (2021) Mechanistic targets and nutritionally relevant intervention strategies to break obesity-breast cancer links. Front Endocrinol (Lausanne) 12:632284.

    Article  Google Scholar 

  6. 6.

    Byrne FL, Martin AR, Kosasih M et al (2020) The role of hyperglycemia in endometrial cancer pathogenesis. Cancers (Basel).

    Article  Google Scholar 

  7. 7.

    Chlebowski RT, Aragaki AK, Anderson GL et al (2020) Dietary modification and breast cancer mortality: long-term follow-up of the women’s health initiative randomized trial. J Clin Oncol 38:1419–1428.

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Choi IY, Chun S, Shin DW et al (2021) Changes in metabolic syndrome status and breast cancer risk: a nationwide cohort study. Cancers (Basel).

    Article  PubMed Central  Google Scholar 

  9. 9.

    Dashti SG, English DR, Simpson JA et al (2021) Adiposity and endometrial cancer risk in postmenopausal women: a sequential causal mediation analysis. Cancer Epidemiol Biomarkers Prev 30:104–113.

    Article  PubMed  CAS  Google Scholar 

  10. 10.

    Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W et al (2018) Effects of aerobic and resistance exercise on metabolic syndrome, sarcopenic obesity, and circulating biomarkers in overweight or obese survivors of breast cancer: a randomized controlled trial. J Clin Oncol 36:875–883.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. 11.

    Dong S, Wang Z, Shen K et al (2021) Metabolic syndrome and breast cancer: prevalence, treatment response, and prognosis. Front Oncol 11:629666.

    Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Esposito K, Chiodini P, Capuano A et al (2014) Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine 45:28–36.

    Article  PubMed  CAS  Google Scholar 

  13. 13.

    Feigelson HS, Bodelon C, Powers JD et al (2021) Body mass index and risk of second cancer among women with breast cancer. J Natl Cancer Inst.

    Article  PubMed  Google Scholar 

  14. 14.

    Fleming S, Jones T, Janda M et al (2020) Physical activity trajectories following gynecological cancer: results from a prospective, longitudinal cohort study. Int J Gynecol Cancer 30:1784–1790.

    Article  PubMed  Google Scholar 

  15. 15.

    Friedenreich CM, Ryder-Burbidge C, McNeil J (2021) Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. Mol Oncol 15:790–800.

    Article  PubMed  Google Scholar 

  16. 16.

    Gong H, Chen Y, Zhou D (2020) Prognostic significance of metformin treatment in endometrial cancer: a meta-analysis. Pharmazie 75:401–406.

    Article  PubMed  CAS  Google Scholar 

  17. 17.

    Hafizz A, Zin RRM, Aziz NHA et al (2020) Beyond lipid-lowering: role of statins in endometrial cancer. Mol Biol Rep 47:8199–8207.

    Article  PubMed  CAS  Google Scholar 

  18. 18.

    Jones T, Sandler C, Vagenas D et al (2021) Physical activity levels among ovarian cancer survivors: a prospective longitudinal cohort study. Int J Gynecol Cancer 31:553–561.

    Article  PubMed  Google Scholar 

  19. 19.

    Kiechle M, Dukatz R, Yahiaoui-Doktor M et al (2017) Feasibility of structured endurance training and Mediterranean diet in BRCA1 and BRCA2 mutation carriers—an interventional randomized controlled multicenter trial (LIBRE-1). BMC Cancer 17:752.

    Article  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Kitson S, Ryan N, MacKintosh ML et al (2018) Interventions for weight reduction in obesity to improve survival in women with endometrial cancer. Cochrane Database Syst Rev 2:CD12513.

    Article  PubMed  Google Scholar 

  21. 21.

    Kitson SJ, Maskell Z, Sivalingam VN et al (2019) PRE-surgical metformin in uterine malignancy (PREMIUM): a multi-center, randomized double-blind, placebo-controlled phase III trial. Clin Cancer Res 25:2424–2432.

    Article  PubMed  CAS  Google Scholar 

  22. 22.

    Kusne YN, Kosiorek HE, Buras MR et al (2020) Mortality and glycemic control among patients with diabetes mellitus and uterine or ovarian cancer. Future Sci OA 7:FSO670.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. 23.

    Kyo S, Nakayama K (2020) Endometrial cancer as a metabolic disease with dysregulated PI3K signaling: shedding light on novel therapeutic strategies. Int J Mol Sci.

    Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Lammert J, Grill S, Kiechle M (2018) Modifiable lifestyle factors: opportunities for (hereditary) breast cancer prevention—a narrative review. Breast Care (Basel) 13:109–114.

    Article  Google Scholar 

  25. 25.

    Li X, Celotto S, Pizzol D et al (2021) Metformin and health outcomes: an umbrella review of systematic reviews with meta-analyses. Eur J Clin Invest.

    Article  PubMed  Google Scholar 

  26. 26.

    Liu B, Giffney HE, Arthur RS et al (2021) Cancer risk in normal weight individuals with metabolic obesity: a narrative review. Cancer Prev Res (Phila) 14:509–520.

    Article  CAS  Google Scholar 

  27. 27.

    Luo J, Chlebowski RT, Hendryx M et al (2017) Intentional weight loss and endometrial cancer risk. J Clin Oncol 35:1189–1193.

    Article  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Luo J, Hendryx M, Manson JE et al (2019) Intentional weight loss and obesity-related cancer risk. JNCI Cancer Spectr 3:pkz54.

    Article  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Matthews CE, Moore SC, Arem H et al (2020) Amount and intensity of leisure-time physical activity and lower cancer risk. J Clin Oncol 38:686–697.

    Article  PubMed  Google Scholar 

  30. 30.

    Michels KA, McNeel TS, Trabert B (2019) Metabolic syndrome and risk of ovarian and fallopian tube cancer in the United States: an analysis of linked SEER-medicare data. Gynecol Oncol 155:294–300.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. 31.

    National Cancer Institute (2017) Obesity and cancer fact sheet. Zugegriffen: 15. Mai 2021

  32. 32.

    Papatla K, Huang M, Slomovitz B (2016) The obese endometrial cancer patient: how do we effectively improve morbidity and mortality in this patient population? Ann Oncol 27:1988–1994.

    Article  PubMed  CAS  Google Scholar 

  33. 33.

    Pescatori S, Berardinelli F, Albanesi J et al (2021) A tale of ice and fire: the dual role for 17beta-estradiol in balancing DNA damage and genome integrity. Cancers (Basel).

    Article  Google Scholar 

  34. 34.

    Premenopausal Breast Cancer Collaborative G, Schoemaker MJ, Nichols HB et al (2018) Association of body mass index and age with subsequent breast cancer risk in premenopausal women. JAMA Oncol 4:e181771.

    Article  Google Scholar 

  35. 35.

    Setiawan VW, Yang HP, Pike MC et al (2013) Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 31:2607–2618.

    Article  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Shively CA, Register TC, Appt SE et al (2018) Consumption of Mediterranean versus western diet leads to distinct mammary gland microbiome populations. Cell Rep 25:47–56.e3.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. 37.

    Simone V, D’Avenia M, Argentiero A et al (2016) Obesity and breast cancer: molecular interconnections and potential clinical applications. Oncologist 21:404–417.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. 38.

    Trabert B, Wentzensen N, Felix AS et al (2015) Metabolic syndrome and risk of endometrial cancer in the united states: a study in the SEER-medicare linked database. Cancer Epidemiol Biomarkers Prev 24:261–267.

    Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Wang L, Wang L, Zhang J et al (2017) Association between diabetes mellitus and subsequent ovarian cancer in women: a systematic review and meta-analysis of cohort studies. Medicine 96:e6396.

    Article  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Wise MR, Jordan V, Lagas A et al (2016) Obesity and endometrial hyperplasia and cancer in premenopausal women: a systematic review. Am J Obstet Gynecol 214:689.e1–689.e17.

    Article  Google Scholar 

  41. 41.

    Yasin HK, Taylor AH, Ayakannu T (2021) A narrative review of the role of diet and lifestyle factors in the development and prevention of endometrial cancer. Cancers (Basel).

    Article  Google Scholar 

  42. 42.

    Zhang X, Haggerty AF, Brown JC et al (2015) The prescription or proscription of exercise in endometrial cancer care. Gynecol Oncol 139:155–159.

    Article  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Zhang X, Rhoades J, Caan BJ et al (2019) Intentional weight loss, weight cycling, and endometrial cancer risk: a systematic review and meta-analysis. Int J Gynecol Cancer 29:1361–1371.

    Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Zhao XB, Ren GS (2016) Diabetes mellitus and prognosis in women with breast cancer: a systematic review and meta-analysis. Medicine 95:e5602.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Günter Emons.

Ethics declarations


G. Emons gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information


QR-Code scannen & Beitrag online lesen


B. Sonntag, Hamburg

G. Emons, Göttingen

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Emons, G. Metabolismus und gynäkologische Krebserkrankungen. Gynäkologe 54, 725–731 (2021).

Download citation


  • Insulin
  • Metabolisches Syndrom
  • Hyperglykämie
  • Inflammation
  • Mikrobiom


  • Insulin
  • Metabolic syndrome
  • Hyperglycemia
  • Inflammation
  • Microbiota